Greene et al. [48] recently proposed that combining SGLT2 inhibitors with angiotensin receptor–neprilysin inhibitors (ARNIs) may lower the risk of hyperkalemia and reduce the likelihood of discontinuing mineralocorticoid receptor antagonists (MRAs). The gene discussed is SLC5A2; the disease is Hyperkalemia.